Scott Boyken, MD
Sports Medicine · Trussville, ALNPI 1245551878
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 1,119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 1,119 payments — averaging $14.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Pfizer$2K
- AbbVie$1K
- Lilly USA, LLC$1K
- Amgen$1K
- AstraZeneca$1K
- plus $6K from 44 others
What the payments were for
- Food & beverage$16,391100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$16,423 in reported general payments places this provider in the 75th percentile of 108 sports medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 228 | $280,860 |
| JardianceEmpagliflozin | 149 | $192,502 |
| EliquisApixaban | 195 | $188,534 |
| TrulicityDulaglutide | 110 | $133,593 |
| MounjaroTirzepatide | 91 | $110,808 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $93,890 |
| LinzessLinaclotide | 81 | $86,427 |
| XareltoRivaroxaban | 43 | $45,218 |
| FarxigaDapagliflozin Propanediol | 53 | $45,096 |
| JanuviaSitagliptin Phosphate | 44 | $42,661 |
| MyrbetriqMirabegron | 51 | $38,877 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $36,018 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $23,066 |
| Repatha SureclickEvolocumab | 26 | $21,744 |
| GemtesaVibegron | 17 | $18,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,279 | $280,860228 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,352 | $244,402201 claims |
| Boehringer IngelheimJardiance | $383 | $192,502149 claims |
| PfizerEliquis | $1,701 | $188,534195 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,079 | $130,024165 claims |
| AbbVieLinzess | $1,442 | $86,42781 claims |
| Johnson & JohnsonXarelto, Invokana | $241 | $52,79956 claims |
| AstraZenecaFarxiga | $1,152 | $45,09653 claims |
| MerckJanuvia | $92 | $42,66144 claims |
| Astellas Pharma US IncMyrbetriq | $187 | $38,87751 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $171 | $18,64817 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $756 | $9,03417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 108 sports medicine providers in Alabama.
Other sports medicine in Trussville
- Edward CainBirmingham$12.7M
- Daniel MatthewsDaphne$190K
- Mark RogersBirmingham$94K
- Amit MomayaBirmingham$77K
- Matthew SmithGuntersville$73K
- Christoper GarrettBirmingham$58K
- Jonathan IsbellHoover$55K
- James McMurtrieHuntsville$54K
- Reaves CrabtreeBirmingham$47K
- David AdkisonBirmingham$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.